| 英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
|---|---|---|---|---|---|---|
|
Elacridar
|
143664-11-3 |
依克立达
|
依克立达;N-[4-[2-(6,7-二甲氧基-3,4-二氢-1H-异喹啉-2-基)乙基]苯基]-5-甲氧基-9-氧代-10H-吖啶-4-甲酰胺;CS-1717;GF 120918;GF120918;GF-120918;ELACRIDAR (GF120918);ELACRIDAR 依克立达;N-{4-[2-(3,4-二氢-6,7-二甲氧基-2(1H)-异喹啉基)乙基]苯基}-9,10-二氢-5-甲氧基-9-氧代-5-吖啶甲酰胺
|
C34H33N3O5 |
563.64 | |
|
KRCA 0008
|
1472795-20-2 |
N/A
|
CS-1715
|
C30H37ClN8O4 |
609.128 | |
|
4-(4-Pyrazolyl)-7-[[2-(trimethylsilyl)ethoxy]methyl]-7H-pyrrolo[2,3-d]pyrimidine
|
941685-27-4 |
4-(1H-吡唑-4-基)-7-((2-(三甲基硅烷基)乙氧基)-甲基)-7H-吡咯并[2,3-D]嘧啶
|
CS-1703;4-(1H-吡唑-4-基)-7-((2-(三甲基硅烷基)乙氧基)-甲基)-7H-吡咯并[2,3-D]嘧啶 巴瑞克替尼中间体 1KG;4-(4-吡唑基)-7-[[2-(三甲基硅基)乙氧基]甲基]-7H-吡咯并[2,3-D]嘧啶;巴瑞克替尼中间体7;4-(1H-吡唑-4-基)-7-((2-(三甲基硅烷基)乙氧基)-甲基)-7H-吡咯并[2,3-D];巴瑞克替尼中间体;4-(1H-吡唑-4-基)-7-((2-(三甲基硅烷基)乙氧基)-甲基)-7H-吡咯并[2,3-D]嘧啶,巴瑞替尼中间体;4-(1H-吡唑-4-基)-7-((2-(三甲基硅烷基)乙氧基)-甲基)-7H-吡咯并[2
|
C15H21N5OSi |
315.451 | 801-232-2 |
|
CAY10683 (SantacruzaMate A)
|
1477949-42-0 |
ETHYL 4-OXO-4-(PHENETHYLAMINO)BUTYLCARBAMATE
|
CS-1702;CAY 10683;CAY-10683;SANTACRUZAMATE A>98%;ETHYL 4-OXO-4-(PHENETHYLAMINO)BUTYLCARBAMATE;HDAC抑制剂
|
C15H22N2O3 |
278.34678 | -0 |
|
GSK-503
|
1346572-63-1 |
N/A
|
CS-1698;GSK-503;GSK503;GSK 503;GSK-503;GSK 503;N-[(4,6-二甲基-2-氧代-1,2-二氢-3-吡啶基)甲基]-3-甲基-1-(异丙基)-6-[6-(4-甲基-1-哌嗪基)-3-吡啶基]-1H-吲哚-4-甲酰胺
|
C31H38N6O2 |
526.67242 | |
|
PLX-647
|
873786-09-5 |
N/A
|
CS-1696;PLX 647;PLX-647
|
C21H17F3N4 |
382.3816896 | |
|
TAE226
|
761437-28-9 |
TAE226 (NVP-TAE226)
|
CS-1694;TAE226 (NVP-TAE226)>98%;TAE226;TAE-226;TAE 226;NVPTAE226;2-[[5-氯-2-[[2-甲氧基-4-(4-吗啉基)苯基]氨基]-4-嘧啶基]氨基]-N-甲基苯甲酰胺;2-[[5-氯-2-[[2-甲氧基-4-(4-吗啉)苯基]氨基]-4-嘧啶]氨基]-N-甲基苯甲酰胺
|
C23H25N6O3Cl |
468.936 | |
|
CARIPORIDE
|
159138-80-4 |
卡立泊来德
|
CS-1692;卡立泊来德;N-(氨基亚氨基甲基)-4-(1-甲基乙基)-3-(甲磺酰基)苯甲酰胺
|
C12H17N3O3S |
283.34668 | 1592732-453-0 |
|
AT7519
|
844442-38-2 |
4-[(2,6-二氯苄基)氨基]-N-4-哌啶1H-吡唑-3-羧胺
|
4-[(2,6-二氯苄基)氨基]-N-4-哌啶1H-吡唑-3-羧胺;N-(4-哌啶基)-4-(2,6-二氯苯甲酰氨基)-1H-吡唑-3-甲酰胺
|
C16H17N5O2Cl2 |
382.24448 | |
|
MK-8245
|
1030612-90-8 |
MK-8245
|
CS-1662;5-[3-[4-(2-溴-5-氟苯氧基)-1-哌啶基]-5-异恶唑基]-2H-四氮唑-2-乙酸;2-(5-(3-(4-(2-溴-5-氟苯氧基)哌啶-1-基)异恶唑-5-基)-2H-四唑-2-基)乙酸;2H-四唑乙酸,5-[3-[4-(2-溴-5-氟苯氧基)-1-哌啶基]-5-异恶唑]-;MK8245;MK-8245;MK 8245;MK 8245;MK8245
|
C17H16N6O4FBr |
467.24914 | |
|
SR9243
|
1613028-81-1 |
N/A
|
CS-1645;N-[2-(3-溴苯基)乙基]-2,4,6-三甲基-N-[[3'-(甲基磺酰基)[1,1'-联苯]-4-基]甲基]苯磺酰胺;SR 9243;SR9243;SR-9243
|
C31H32BrNO4S2 |
626.62408 | |
|
SBE-13 Hydrochloride
|
1052532-15-6 |
N/A
|
CS-1632;N-[[4-[(6-氯-3-吡啶基)甲氧基]-3-甲氧基苯基]甲基]-3,4-二甲氧基苯乙胺盐酸盐
|
C24H28Cl2N2O4 |
479.39612 | |
|
Purvalanol A
|
212844-53-6 |
PURVALANOL A
|
PURVALANOLA>98%;NG 60;NG60;NG-60
|
C19H25N6OCl |
388.8944 | |
|
AM095
|
1228690-36-5 |
[4'-[3-甲基-4-[[[((R)-1-苯基乙基)氧基]羰基]氨基]异恶唑-5-基]联苯-4-基]乙酸
|
AM-095 (free base);AM095 (free acid);[4'-[3-Methyl-4-[[[((R)-1-phenylethyl)oxy]carbonyl]amino]isoxazol-5-yl]biphenyl-4-yl]acetic acid;AM 095 (parent compound);2-[4-[4-[3-methyl-4-[[(1r)-1-phenylethoxy]carbonylamino]-1,2-oxazol-5-yl]phenyl]phenyl]acetic Acid
|
C27H24N2O5 |
456.48986 | |
|
LY2409881
|
946518-60-1 |
N/A
|
2-[5-氯-2-[[3-(4-甲基-1-哌嗪基)丙基]氨基]-4-嘧啶基]-N-环丙基-苯并[B]噻吩-4-甲酰胺三盐酸盐;LY-2409881 ;LY 2409881;CS-1620
|
C24H32Cl4N6OS |
594.42748 | |
|
FIIN-2
|
1633044-56-0 |
FIIN-2
|
N-[4-[[3-(3,5-二甲氧基苯基)-3,4-二氢-7-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-2-氧代嘧啶并[4,5-D]嘧啶-1(2H)-基]甲基]苯基]-2-丙烯酰胺
|
C35H38N8O4 |
634.72742 | |
|
GSK2801
|
1619994-68-1 |
GSK2801
|
1-[1-[2-(甲基磺酰基)苯基]-7-丙氧基-3-吲哚嗪基]乙酮;GSK2801>98%;GSK2801;GSK-2801;GSK 2801;CS-1607;GSK-2801;GSK 280
|
C20H21NO4S |
371.45004 | |
|
HA-130
|
1229652-21-4 |
N/A
|
HA130;HA-130;HA 130;CS-1606
|
C24H19BFNO5S |
463.285763 | |
|
AVN-944
|
297730-17-7 |
N/A
|
VX 944;VX944;[(2R)-1-cyanobutan-2-yl] N-[(1S)-1-[3-[[3-methoxy-4-(1,3-oxazol-5-yl)phenyl]carbamoylamino]phenyl]ethyl]carbamate;VX-944;AVN944 (VX-944);(R)-1-cyanobutan-2-yl (S)-1-(3-(3-(3-methoxy-4-(oxazol-5-yl)phenyl)ureido)phenyl)ethylcarbamate
|
C25H27N5O5 |
477.5183 | |
|
CEP-37440
|
1391712-60-9 |
CEP-37440
|
CEP37440;CEP 37440;CS-1603
|
C30H38ClN7O3 |
580.12082 | 200-258-5 |
药智官方微信
药智官方微博
